A Decade of Scientific, Clinical & Commercial Breakthroughs
From a niche area of immunology to one of the most exciting frontiers in drug development, the complement field has undergone a remarkable transformation. What was once considered a challenging therapeutic target has become a proven source of life-changing medicines, attracting major pharmaceutical investment, generating multiple approved therapies, and validating entirely new approaches to immune modulation. Today, complement-targeted treatments are transforming outcomes across haematology, nephrology, ophthalmology, neurology and beyond, with the next generation of therapies poised to reach even broader patient populations.
As we celebrate 10 years of the Complement-Based Drug Development Summit, we look back at 10 milestones that have shaped the evolution of the field:
Complement Inhibition Becomes a Clinical Reality
The approval of Soliris® (eculizumab) for PNH established the first successful complement-targeted therapy, proving that complement inhibition could deliver meaningful clinical benefit and create a new therapeutic industry.
Rare Disease Patients Gain Transformative Treatment Options
Expansion into atypical haemolytic uraemic syndrome (aHUS) demonstrated the profound impact complement therapies could have on severe complement-mediated diseases, transforming standards of care and patient outcomes.
A Thriving Complement Biotech Ecosystem Emerges
The success of early therapies catalysed the growth of a new generation of complement-focused companies, including Apellis, Annexon, Omeros, Amyndas, BioCryst and others, driving innovation across the cascade.
Drug Discovery Expands Beyond C5
Development of C3, Factor B, Factor H, Factor D, C1s and C5a-targeted therapies proved that the complement cascade offers multiple druggable intervention points, opening the door to more precise and differentiated therapeutic strategies.
The First C3 Inhibitor Reaches Patients
The approval of pegcetacoplan marked a landmark moment for the field, validating upstream complement inhibition and demonstrating that alternative mechanisms could address limitations of first-generation therapies.
Complement Expands Beyond Rare Haematology
Clinical and commercial success in nephrology, ophthalmology and autoimmune disease confirmed complement's role across multiple therapeutic areas, significantly broadening the field’s potential impact.
Geographic Atrophy Becomes a Major Clinical & Commercial Validation
The approval of complement-targeted therapies for geographic atrophy provided one of the field's most significant expansions into large patient populations, highlighting the commercial and clinical potential of complement modulation beyond rare disease.
Oral Complement Therapies Enter the Clinic
The emergence of oral medicines such as factor B inhibitors signalled a major shift in patient convenience and treatment accessibility, demonstrating the maturation of complement drug development.
Complement Becomes a Mainstream Pharmaceutical Priority
Growing investment, partnerships, acquisitions and pipeline activity from major pharmaceutical companies validated complement as a strategically important therapeutic area and accelerated development across numerous indications.
A New Generation of Complement Medicines Arrives
Today, the field has progressed from a single approved therapy to a broad portfolio of approved drugs and clinical-stage programs spanning multiple mechanisms, indications and modalities, with continued momentum expected across kidney disease, neurodegeneration, ophthalmology, autoimmune disorders and rare disease.
Looking Ahead
As the Complement-Based Drug Development Summit reaches its 10th year, the field stands at an inflection point. With unprecedented scientific understanding, multiple validated targets, expanding clinical success and growing commercial investment, complement is no longer an emerging opportunity. It is a proven therapeutic pillar shaping the future of immunology and precision medicine. The next decade promises to be even more transformative than the last.